Biolidics Limited (SGX: 8YY)
Singapore
· Delayed Price · Currency is SGD 0.0140
+0.0010 (7.69%)
At close: Dec 3, 2024
Biolidics Income Statement
Financials in millions SGD. Fiscal year is January - December.
Millions SGD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2015 |
| Operating Revenue | 1.2 | 1.32 | 2.49 | 2.31 | 8.91 | 1.44 | Upgrade
|
| Other Revenue | 0.08 | 0.05 | 0.17 | 0.02 | 0.37 | 0.09 | Upgrade
|
| Revenue | 1.28 | 1.36 | 2.66 | 2.33 | 9.27 | 1.53 | Upgrade
|
| Revenue Growth (YoY) | 4.82% | -48.85% | 14.26% | -74.88% | 507.89% | 15.83% | Upgrade
|
| Cost of Revenue | 0.7 | 0.77 | 1.37 | 2.19 | 5.47 | 0.47 | Upgrade
|
| Gross Profit | 0.58 | 0.59 | 1.3 | 0.14 | 3.8 | 1.05 | Upgrade
|
| Selling, General & Admin | 1.76 | 1.66 | 2.89 | 1.65 | 2.76 | 1.52 | Upgrade
|
| Research & Development | 0.03 | 0.03 | 0.23 | 1.09 | 0.88 | 1.23 | Upgrade
|
| Other Operating Expenses | 1.46 | 1.05 | 2.67 | 2.33 | 3.38 | 2.46 | Upgrade
|
| Operating Expenses | 3.55 | 3.06 | 7.06 | 6.32 | 8.02 | 5.85 | Upgrade
|
| Operating Income | -2.98 | -2.47 | -5.76 | -6.18 | -4.21 | -4.79 | Upgrade
|
| Interest Expense | -0.06 | -0.11 | -0.17 | -0.21 | -0.13 | -0.01 | Upgrade
|
| Interest & Investment Income | 0.04 | 0.08 | - | 0 | 0.03 | 0.11 | Upgrade
|
| Currency Exchange Gain (Loss) | 0 | - | 0.09 | 0.08 | -0.55 | -0.01 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.03 | 0.01 | 0.03 | 0.08 | 0 | - | Upgrade
|
| EBT Excluding Unusual Items | -2.96 | -2.49 | -5.81 | -6.22 | -4.85 | -4.7 | Upgrade
|
| Impairment of Goodwill | - | - | -0.63 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | - | 0.02 | Upgrade
|
| Asset Writedown | - | - | -3.42 | - | -0.06 | -0.13 | Upgrade
|
| Other Unusual Items | 0.01 | - | - | 0.18 | 0.23 | - | Upgrade
|
| Pretax Income | -2.95 | -2.49 | -9.85 | -6.04 | -4.68 | -4.81 | Upgrade
|
| Income Tax Expense | - | - | -0.48 | -0.06 | -0.03 | - | Upgrade
|
| Net Income | -2.81 | -2.49 | -9.37 | -5.98 | -4.65 | -4.81 | Upgrade
|
| Net Income to Common | -2.81 | -2.49 | -9.37 | -5.98 | -4.65 | -4.81 | Upgrade
|
| Shares Outstanding (Basic) | 743 | 593 | 282 | 265 | 257 | 243 | Upgrade
|
| Shares Outstanding (Diluted) | 743 | 593 | 282 | 265 | 257 | 243 | Upgrade
|
| Shares Change (YoY) | 53.94% | 110.56% | 6.21% | 3.01% | 6.17% | 92.20% | Upgrade
|
| EPS (Basic) | -0.00 | -0.00 | -0.03 | -0.02 | -0.02 | -0.02 | Upgrade
|
| EPS (Diluted) | -0.00 | -0.00 | -0.03 | -0.02 | -0.02 | -0.02 | Upgrade
|
| Free Cash Flow | -2.03 | -1.97 | -3.1 | -5.07 | -2.76 | -5.12 | Upgrade
|
| Free Cash Flow Per Share | -0.00 | -0.00 | -0.01 | -0.02 | -0.01 | -0.02 | Upgrade
|
| Gross Margin | 45.16% | 43.13% | 48.67% | 5.97% | 41.03% | 69.06% | Upgrade
|
| Operating Margin | -232.06% | -181.34% | -216.61% | -265.22% | -45.42% | -314.29% | Upgrade
|
| Profit Margin | -219.11% | -182.81% | -352.27% | -256.93% | -50.15% | -315.29% | Upgrade
|
| Free Cash Flow Margin | -157.96% | -144.45% | -116.38% | -217.65% | -29.72% | -335.58% | Upgrade
|
| EBITDA | -2.97 | -2.41 | -4.9 | -5.3 | -3.52 | -4.43 | Upgrade
|
| EBITDA Margin | -231.59% | -177.30% | -184.10% | -227.35% | -37.91% | -290.50% | Upgrade
|
| D&A For EBITDA | 0.01 | 0.06 | 0.87 | 0.88 | 0.7 | 0.36 | Upgrade
|
| EBIT | -2.98 | -2.47 | -5.76 | -6.18 | -4.21 | -4.79 | Upgrade
|
| EBIT Margin | -232.06% | -181.34% | -216.61% | -265.22% | -45.42% | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.